TY - JOUR
T1 - Increased pulmonary vascular resistance with systemic hypertension. Effect of minoxidil and other antihypertensive agents
AU - Atkins, James M
AU - Mitchell, Helen C.
AU - Pettinger, William A.
N1 - Funding Information:
From the University of Texas Southwestern Medical School, Department of Internal Medicine and Pharmacology, Division of Clinical Pharmacology, Dallas, Texas. * Burroughs-Wellcome Scholar in Clinical Pharmacology. This project was funded by the Harry S. Moss Heart Fund, Dallas, Texas and a grant from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Manuscript received September 23, 1976; revised manuscript received December 27, 1976, accepted December 29, 1976. Address for reprints: James M. Atkins, MD, Department of Internal Medicine, The University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, Texas 75235.
PY - 1977
Y1 - 1977
N2 - Recent case reports suggest that pulmonary hypertension could be caused by minoxidil, a new potent vasodilating antihypertensive drug. Therefore, we evaluated the incidence and severity of pulmonary hypertension in 110 patients with systemic hypertension. Fourteen patients were treated with minoxidil for 2 to 35 months (mean 19.9 months), 15 were treated with no drugs, and the remaining 81 patients received conventional antihypertensive agents of several types. Pulmonary vascular resistance correlated positively (P < 0.05) with systemic vascular resistance. Minoxidil-treated patients with hypertension previously refractory to conventional therapy had slightly lower pulmonary vascular resistance than other hypertensive subjects. There was no correlation between pulmonary vascular resistance and duration of minoxidil therapy or other types of antihypertensive regimens. The positive correlation between pulmonary and systemic vascular resistance suggests the possibility of a causal hypertensive relation in the two vascular beds.
AB - Recent case reports suggest that pulmonary hypertension could be caused by minoxidil, a new potent vasodilating antihypertensive drug. Therefore, we evaluated the incidence and severity of pulmonary hypertension in 110 patients with systemic hypertension. Fourteen patients were treated with minoxidil for 2 to 35 months (mean 19.9 months), 15 were treated with no drugs, and the remaining 81 patients received conventional antihypertensive agents of several types. Pulmonary vascular resistance correlated positively (P < 0.05) with systemic vascular resistance. Minoxidil-treated patients with hypertension previously refractory to conventional therapy had slightly lower pulmonary vascular resistance than other hypertensive subjects. There was no correlation between pulmonary vascular resistance and duration of minoxidil therapy or other types of antihypertensive regimens. The positive correlation between pulmonary and systemic vascular resistance suggests the possibility of a causal hypertensive relation in the two vascular beds.
UR - http://www.scopus.com/inward/record.url?scp=0017706191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017706191&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(77)80030-1
DO - 10.1016/S0002-9149(77)80030-1
M3 - Article
C2 - 871107
AN - SCOPUS:0017706191
SN - 0002-9149
VL - 39
SP - 802
EP - 807
JO - The American journal of cardiology
JF - The American journal of cardiology
IS - 6
ER -